Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET

Company Participants

Joey Perrone - SVP, Finance and IR
Jeremy Bender - CEO
Lauren Merendino - CCO
Samuel Blackman - Co-Founder and Head, R&D
Charles York - COO and CFO

Conference Call Participants

Anupam Rama - JPMorgan
Joe Catanzaro - Piper Sandler
Andrea Newkirk - Goldman Sachs
Soumit Roy - Jones Research
Alec Stranahan - Bank of America
Ami Fadia - Needham & Company
Andres Maldonado - H.C. Wainwright

Operator

Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals' Third Quarter of 2024 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded.

I would now like to turn the conference call over to Joey Perrone, Senior Vice President of Finance and Investor Relations. Please go ahead, sir.

Joey Perrone

Thank you. Hello, everyone, and good afternoon. Welcome to Day One's third quarter 2024 financial and operating results conference call. Earlier today, we issued a press release, which outlines the topics we plan to discuss today.

You can access the press release and the slides to accompany this conference call on the Investors and Media section of our website at www.day1bio.com. An audio webcast with the corresponding slides is also available on the website.

Before we get started, I'd like to remind everyone that some of the statements that we make on this call and information presented in the slide deck includes forward-looking statements as outlined on Slide 2.

Actual events and results could differ materially from those expressed or implied by any forward-looking statements. We encourage you to review the various risks, uncertainties and other factors included in our most recent filings with the SEC and any other future filings that we may make with the SEC.

These forward-looking statements are based on our current estimates and various assumptions and reflect management's intentions, beliefs and expectations about future events, strategies, competition, products and product candidates, operating plans and performance.

You are cautioned not to place any undue reliance on these forward-looking statements, and except as required by law, Day One disclaims any obligation to update such statements.

Today, I am joined by Dr. Jeremy Bender, Chief Executive Officer; Lauren Merendino, Chief Commercial Officer; Charles York, Chief Operating and Financial Officer; and Dr. Samuel Blackman, Co-Founder and Head of R&D.

I will now turn the call over to Jeremy.